Immatics N.V. Interest Expense 2011-2026 | IMTX

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Quarterly Interest Expense Immatics N.V.

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	140 K	-	-	-	81 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in EUR currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
140 K	81 K	110 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Lipocine LPCN	27.1 K	$ 7.4	1.23 %	$ 39 M	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Aileron Therapeutics ALRN	685 K	-	10.36 %	$ 9.8 M	USA
Ascendis Pharma A/S ASND	80.6 M	$ 217.23	-0.38 %	$ 5 B	Danmark
Amphastar Pharmaceuticals AMPH	23 K	$ 19.47	1.25 %	$ 910 M	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
Corbus Pharmaceuticals Holdings CRBP	1.24 M	$ 8.28	-1.84 %	$ 110 M	USA
Lexicon Pharmaceuticals LXRX	6.91 M	$ 1.68	2.13 %	$ 610 M	USA
AgeX Therapeutics AGE	4.9 M	-	-10.17 %	$ 12.2 K	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Exelixis EXEL	-198 K	$ 41.51	0.23 %	$ 11.3 B	USA
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
Autolus Therapeutics plc AUTL	9.29 M	$ 1.36	-3.21 %	$ 347 M	Britain
Mesoblast Limited MESO	16.9 M	$ 14.31	2.07 %	$ 9.29 B	Australia
ChemoCentryx CCXI	2.7 M	-	-	$ 3.74 B	USA
Aytu BioScience AYTU	-512 K	$ 2.61	-0.76 %	$ 16.4 M	USA
Atreca BCEL	3 K	-	-11.76 %	$ 5.79 M	USA
BioDelivery Sciences International BDSI	-6 K	-	-4.8 %	$ 255 M	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
BeiGene, Ltd. BGNE	-42.6 M	-	0.49 %	$ 251 B	Cayman-islands
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Arbutus Biopharma Corporation ABUS	459 K	$ 4.34	-1.92 %	$ 832 M	Canada
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Ionis Pharmaceuticals IONS	17.3 M	$ 69.55	-1.75 %	$ 11.1 B	USA
Allakos ALLK	8 K	-	-	$ 28.6 M	USA
Brickell Biotech BBI	5 K	-	-5.38 %	$ 6.06 M	USA
Longeveron LGVN	680 K	$ 0.87	-8.8 %	$ 15.3 B	USA
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA